Related Experiment Video
Updated: May 24, 2025
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma
Vinita Akula1, Lily Chen1, Yusuf Acikgoz2
1Department of Internal Medicine, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
Abstract:
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.
